ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiota modulations After kidney transplantation - ENIGMA

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508335-31-00

Acronym

ENIGMA

Enrollment

Registered

2024-03-18

Start date

2024-09-02

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Brief summary

Immunosuppressive drug pharmacokinetic parameters, including tacrolimus, mycophenolic acid (the active moiety of mycophenolate mofetil) and glucuronides (MPA-glucuronide and acyl-MPA-glucuronide). Microbiota composition and function. Antibiotic pharmacokinetics

Interventions

DRUGTACROLIMUS MONOHYDRATE

DRUGMYCOPHENOLATE MOFETIL

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Immunosuppressive drug pharmacokinetic parameters, including tacrolimus, mycophenolic acid (the active moiety of mycophenolate mofetil) and glucuronides (MPA-glucuronide and acyl-MPA-glucuronide). Microbiota composition and function. Antibiotic pharmacokinetics	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026